RE:RE:The RBC report for April-21-2016It's factored in the price guys. Even if donnatel sales drop 40% and since it accounts for 10% of total Cxr sales, then that's only a 4% drop to the total sales. That brings the SP to the 60s in worst case scenario, not 30s. I read reports from many of the banks that cover Cxr detailing almost every significant drug from amco, the moving parts are very volatile and in constant motion. It's the sum of all the parts that will make Cxr a well balanced real generic drug company. I'm not saying it's a $75 stock, I'm saying its definitely not a $30 stock. If there is no agreement to sell, the only way Cxr can recover its SP to proper level is by paying off the debt fast, it's that simple. By doing so they are saving 8% on every dollar they pay off which will be used to payoff more debt. Restructuring the debt is also a real "strategic alternative" they will catapult the share price. We have bankers running this company, let's hope they are capable of using their financial engeneering skill for something other than increase drug prices.